Molecular Partners AG
SIX:MOLN
Molecular Partners AG
Income from Continuing Operations
Molecular Partners AG
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Molecular Partners AG
SIX:MOLN
|
Income from Continuing Operations
-CHf84.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Income from Continuing Operations
-$234.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
Income from Continuing Operations
-CHf54.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Income from Continuing Operations
-$217.1m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Income from Continuing Operations
CHf10.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
SIX:IDIA
|
Income from Continuing Operations
-CHf297.9m
|
CAGR 3-Years
13%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
See Also
What is Molecular Partners AG's Income from Continuing Operations?
Income from Continuing Operations
-84.7m
CHF
Based on the financial report for Mar 31, 2024, Molecular Partners AG's Income from Continuing Operations amounts to -84.7m CHF.